Synthesis, SAR study and biological evaluation of novel pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as anti-proliferative agents
作者:Yanong D. Wang、Erick Honores、Biqi Wu、Steve Johnson、Dennis Powell、Miriam Miranda、John P. McGinnis、Carolyn Discafani、Sridhar K. Rabindran、Wendy Cheng、Girija Krishnamurthy
DOI:10.1016/j.bmc.2008.12.046
日期:2009.3
upstream activator, p53, and is associated with poor prognosis in some cancer patients. Using an isogenic pair of cell lines, HCT116 (p21+/+) and 80S14 (p21−/−), we have disclosed previously a novel series of pyrazolo[1,5-a]pyrimidines that preferentially kill the p21-deficient cells. We will present the synthesis, biological activities and SAR study of a series of pyrazolo[1,5-a]pyrimidines with an
恶性细胞检查点不足可用于开发癌症药物。可以选择性地杀死缺乏检查点的细胞和具有检查点的细胞的化合物来优先靶向肿瘤细胞,同时保留正常细胞。蛋白质p21 Wafl / Cipl / Sdi1(下文称为p21)通过抑制G1激酶(cyclin D / cdk4和cyclin E-cdk2)和G2激酶(cyclin B / cdkl)的活性来抑制细胞周期的进展,以响应DNA损伤或异常DNA含量。由于上游激活因子p53的频繁丢失,人癌细胞中p21的表达通常较低,并且与某些癌症患者的预后不良有关。使用同等基因对的细胞系HCT116(p21 + / +)和80S14(p21-/-),我们先前已经公开了一系列新颖的吡唑并[1,5- a ]嘧啶,可优先杀死p21缺陷型细胞。我们将介绍一系列吡唑并[1,5- a在C-7位置具有优化的苯基酰胺部分的]嘧啶。这些化合物的作用机理也将被讨论。